Femara (letrozole) - Start Strong

FOR NON US HEALTHCARE PROFESSIONALS ONLY FOR U.S. RESIDENTS NOVARTIS ONCOLOGY

Learn More About Adjuvant Therapy Click here for more

CLINICAL TRIAL IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER STUDY RESULTS. FEMARA now approved as adjuvant therapy for early breast cancer

RECENT PUBLICATIONS

Crivellari, et al.
Letrozole Compared With Tamoxifen for Elderly Patients with Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial Click here
Journal of Clinical Oncology (April 2008)

Mouridsen HT. 
Letrozole in advanced breast cancer: the PO25 trial.
Breast Cancer Res Treat. (2007 February [Epub ahead of print])

Mauriac L, Keshaviah A, Debled M, et al. 
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Annals of Oncology (2007 February [Epub ahead of print])

Coates AS, Keshaviah A, Thurlimann B, et al. 
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Journal of Clinical Oncology. (2007 February)

Gluck S. 
The prevention and management of distant metastases in women with breast cancer.
Cancer Invest. (2007 January)

Femara Mechanism of Action

Femara Mechanism of Action , a short animation on how Femara works.

EXTENDED ADJUVANT THERAPY

For detailed information about Extended Adjuvant Therapy Click here